New once-daily weight loss pill now available in pharmacies across UK
Eli Lilly's new weight loss and diabetes pill, orforglipron (Foundayo), is now available in UK pharmacies. It's the second GLP-1 pill for weight loss in the UK, after Wegovy. The MHRA authorized it earlier this month. Eli Lilly is working with the NHS on potential health service rollout. The pill is for patients with BMI 30+ or BMI 27-30 with weight-related conditions. Dosage starts at 0.8mg, increasing monthly. Pharmacists highlight its significance for patients avoiding injectables.
How this was made
The 30-second read
Why it matters
The approval expands Lilly's product pipeline into oral therapy, likely enhancing its market share in the growing obesity treatment space.
Market read
Regulatory approval of a novel oral weight‑loss drug could drive earnings growth for Lilly and affect the broader GLP‑1 market.
What to watch
Potential competition from injectable GLP‑1s and the need for real‑world adherence data.
Background
The article announces the UK launch of an oral GLP‑1 weight‑loss pill by Eli Lilly, the first such approval in Europe.
Ticker impact
Eli Lilly received MHRA approval for its oral GLP‑1 weight‑loss pill Foundayo (orforglipron) in the UK, marking the first European launch of the drug.
Modest upside as investors price in future UK sales and potential NHS adoption.
Large‑cap pharma with proven GLP‑1 demand; UK approval is a fresh catalyst with no prior coverage.
Market effects
Strengthens the weight‑loss/diabetes therapeutic sector and may pressure peers to accelerate oral GLP‑1 development.
Adds a new prescription option for UK patients, potentially influencing NHS formulary decisions.
First European approval could pave the way for broader rollout across Europe.
Counterpoint
UK launch may be limited by NHS budget constraints and pricing negotiations, tempering upside.
Key entities
- CompanyEli Lilly
US‑listed pharmaceutical company developing the oral GLP‑1 drug.
- RegulatorMHRA
UK Medicines and Healthcare products Regulatory Agency that granted approval.
